Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status

被引:83
作者
Romano, Andrea [1 ,2 ]
Calabria, L. F. [1 ]
Tavanti, F. [1 ]
Minniti, G. [3 ]
Rossi-Espagnet, M. C. [1 ]
Coppola, V. [1 ]
Pugliese, S. [1 ]
Guida, D. [1 ]
Francione, G. [1 ]
Colonnese, C. [4 ,5 ]
Fantozzi, L. M. [1 ]
Bozzao, A. [1 ]
机构
[1] Univ Roma La Sapienza, Dept Neuroradiol, NESMOS, S Andrea Hosp, Rome, Italy
[2] IRCSS San Raffaele Pisana, Rome, Italy
[3] Univ Roma La Sapienza, Dept Radiotherapy, S Andrea Hosp, Rome, Italy
[4] Univ Sapienza, IRCSS Neuromed, Dept Neuroradiol, Pozzilli, Italy
[5] Univ Roma La Sapienza, Umberto Hosp 1, Dept Neuroradiol, Rome, Italy
关键词
Methylation status of MGMT promoter; Apparent diffusion coefficient; Overall survival; Progression-free survival; Glioblastoma multiforme; CONCOMITANT RADIOCHEMOTHERAPY; METHYLTRANSFERASE; PROGRESSION; GLIOMAS; RADIOTHERAPY; PERFUSION; PSEUDOPROGRESSION; SPECTROSCOPY; CHEMOTHERAPY; TEMOZOLOMIDE;
D O I
10.1007/s00330-012-2601-4
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
To evaluate whether apparent diffusion coefficient (ADC) values can predict the status of MGMT of glioblastoma multiforme (GBM) and correlate with overall survival (OS) and progression-free survival (PFS). This retrospective study included 47 patients with pathologically proven glioblastoma. All of them underwent MR DWI study before surgery (mean time 1 week) and the status of methylguanine-DNA-methyltransferase (MGMT) promoter methylation was searched for. Minimum apparent diffusion coefficient (ADC) values were evaluated. OS and PSF parameters were calculated, and Student's t-test, Kaplan-Meier curves, linear and Cox regression were performed. Twenty-five patients showed positive methylation of the MGMT promoter. Patients showing MGMT promoter methylation had higher minimum ADC values, and they survived longer than those without MGMT promoter methylation. The median ADCmin value of 0.80 represents the cutoff value able to distinguish between methylated and un-methylated patients. Patients showing minimum ADC values higher than 0.80 survived longer than patients with minimum ADC values lower than 0.80. A linear correlation between minimum ADC values vs. the OS and PFS was observed. Minimum ADC values in glioblastoma multiforme could be used as a preoperative parameter to estimate the status of MGMT promoter methylation and the survival of patients. aEuro cent Diffusion-weighted MR imaging (DWI) provides new insights into glioblastoma multiforme (GBM) aEuro cent DWI ADCmin values can predict the methylation status of MGMT promoter. aEuro cent The MGMT promoter methylation group survived longer than the unmethylated group. aEuro cent Patients with high ADCmin values survived longer than patients with low values.
引用
收藏
页码:513 / 520
页数:8
相关论文
共 34 条
[1]   RETRACTED: Glioma grading: sensitivity, specificity, positive and negative predictive values of diffusion and perfusion imaging (Retracted article. See vol. 114, pg. 255, 2013) [J].
Arvinda, H. R. ;
Kesavadas, C. ;
Sarma, P. S. ;
Thomas, B. ;
Radhakrishnan, V. V. ;
Gupta, A. K. ;
Kapilamoorthy, T. R. ;
Nair, S. .
JOURNAL OF NEURO-ONCOLOGY, 2009, 94 (01) :87-96
[2]   Glioblastoma Multiforme Regional Genetic and Cellular Expression Patterns: Influence on Anatomic and Physiologic MR Imaging [J].
Barajas, Ramon F., Jr. ;
Hodgson, J. Graeme ;
Chang, Jamie S. ;
Vandenberg, Scott R. ;
Yeh, Ru-Fang ;
Parsa, Andrew T. ;
McDermott, Michael W. ;
Berger, Mitchel S. ;
Dillon, William P. ;
Cha, Soonmee .
RADIOLOGY, 2010, 254 (02) :564-576
[3]   Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology [J].
Brandes, Alba A. ;
Tosoni, Alicia ;
Spagnolli, Federica ;
Frezza, Giarnpiero ;
Leonardi, Marco ;
Calbucci, Fabio ;
Franceschi, Enrico .
NEURO-ONCOLOGY, 2008, 10 (03) :361-367
[4]   MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients [J].
Brandes, Alba A. ;
Franceschi, Enrico ;
Tosoni, Alicia ;
Blatt, Valeria ;
Pession, Annalisa ;
Tallini, Giovanni ;
Bertorelle, Roberta ;
Bartolini, Stefania ;
Calbucci, Fabio ;
Andreoli, Alvaro ;
Frezza, Giampiero ;
Leonardi, Marco ;
Spagnolli, Federica ;
Ermani, Mario .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) :2192-2197
[5]   The added value of the apparent diffusion coefficient calculation to magnetic resonance imaging in the differentiation and grading of malignant brain tumors [J].
Bulakbasi, N ;
Guvenc, I ;
Onguru, O ;
Erdogan, E ;
Tayfun, C ;
Ucoz, T .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 2004, 28 (06) :735-746
[6]   Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors [J].
Calli, Cem ;
Kitis, Omer ;
Yunten, Nigun ;
Yurtseven, Taskin ;
Islekel, Sertac ;
Akalin, Taner .
EUROPEAN JOURNAL OF RADIOLOGY, 2006, 58 (03) :394-403
[7]   Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma [J].
Chamberlain, Marc C. ;
Glantz, Michael J. ;
Chalmers, Lisa ;
Van Horn, Alixis ;
Sloan, Andrew E. .
JOURNAL OF NEURO-ONCOLOGY, 2007, 82 (01) :81-83
[8]   An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging [J].
Drabycz, Sylvia ;
Roldan, Gloria ;
de Robles, Paula ;
Adler, Daniel ;
McIntyre, John B. ;
Magliocco, Anthony M. ;
Cairncross, J. Gregory ;
Mitchell, J. Ross .
NEUROIMAGE, 2010, 49 (02) :1398-1405
[9]   Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival [J].
Eoli, Marica ;
Menghi, Francesca ;
Bruzzone, Maria Grazia ;
De Simone, Tiziana ;
Valletta, Lorella ;
Pollo, Bianca ;
Bissola, Lorena ;
Silvani, Antonio ;
Bianchessi, Donatella ;
D'Incerti, Ludovico ;
Filippini, Graziella ;
Broggi, Giovanni ;
Boiardi, Amerigo ;
Finocchiaro, Gaetano .
CLINICAL CANCER RESEARCH, 2007, 13 (09) :2606-2613
[10]   Clinical relevance of MGMT in the treatment of cancer [J].
Gerson, SL .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (09) :2388-2399